Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 2/20 | 0.59 |
| ▸ | GOPC | Q9HD26 | 2/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | KCNA5 | P22460 | 7/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.51 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | KCNN4 | O15554 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL5999698 | 0.98 | CFTR (0.57) | CFTRGOPCSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL658876 | 0.96 | CFTR (0.57) | CFTRGOPCSLC6A2SLC6A4SLC6A3 | |
| Ammonia Solution, Strong SCHEMBL6000373 | 0.88 | CFTR (0.46) | CFTRGOPCSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11737642 | 0.88 | CYP19A1 (0.62) | CFTRGOPCSLC6A2SLC6A4SLC6A3 | |
| Ammonia Solution, Strong SCHEMBL5999435 | 0.86 | POLB (0.50) | CFTRGOPCSLC6A2SLC6A4SLC6A3 | |
| Ammonia Solution, Strong SCHEMBL5999471 | 0.86 | SLC6A4 (0.44) | CFTRGOPCSLC6A2SLC6A4SLC6A3 | |
| Ammonia Solution, Strong SCHEMBL6000489 | 0.86 | CYP19A1 (0.60) | CFTRGOPCSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL23970158 | 0.85 | TBXAS1 (0.56) | CFTRGOPCSLC6A2SLC6A4SLC6A3 | |
| Ammonia Solution, Strong SCHEMBL5999968 | 0.84 | CYP17A1 (0.61) | CFTRGOPCSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10219854 | 0.82 | CYP11B1 (0.56) | CFTRGOPCSLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0214793-A1 | (2-Cyano-2-arylethyl)pyridines, their preparation and use as fungicides | ROHM AND HAAS COMPANY (US) | 1987-03-18 | — | — | EP | claimed |
| US-20230295181-A1 | INHIBITOR OF APOPTOSIS (IAP) PROTEIN ANTAGONISTS | Sanford Burnham Prebys Medical Discovery Institute | 2023-09-21 | — | — | US | disclosed |
| EP-3904330-A1 | ETHYLENEDIAMINE COMPOUND AND USE THEREOF | Academy Of Military Medical Sciences (CN) | 2021-11-03 | — | — | EP | disclosed |
| EP-2620436-B1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | SHIONOGI & CO (JP) | 2018-05-09 | — | — | EP | disclosed |
| US-20170349587-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | SHIONOGI & CO., LTD. (JP) | 2017-12-07 | — | — | US | disclosed |
| US-8334252-B2 | Perfume-containing hollow body consisting of a polymer matrix | SYMRISE AG (DE) | 2012-12-18 | — | — | US | disclosed |
| US-20110130320-A1 | PERFUME-CONTAINING HOLLOW BODY CONSISTING OF A POLYMER MATRIX | SYMRISE AG (DE) | 2011-06-02 | — | — | US | disclosed |
| US-7825136-B2 | Potentiators of antibacterial activity | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-02 | — | — | US | disclosed |
| US-20050090482-A1 | mixture of antibiotics, carriers and activators such as (S)-1-((3,4,5-Trimethoxyphenyl)-methyl-carbamoyl)-piperidine-2-carboxylic acid 4-pyridin-3-yl-1-(3-pyridin-3-yl-propyl)-butyl ester, used for treatment of bacterial infection in mammals | VERTEX PHARMACEUTICALS INCORPORATED | 2005-04-28 | — | — | US | disclosed |
| US-6326387-B1 | NEUROTROPIC COMPOUND | VERTEX PHARMACEUTICALS INCORPORATED | 2001-12-04 | — | — | US | disclosed |
| US-4116665-A | Method of regulating the growth of aquatic weeds with pyridine derivatives | ELI LILLY AND COMPANY (US) | 1978-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090482-A1 | mixture of antibiotics, carriers and activators such as (S)-1-((3,4,5-Trimethoxyphenyl)-methyl-carbamoyl)-piperidine-2-carboxylic acid 4-pyridin-3-yl-1-(3-pyridin-3-yl-propyl)-butyl ester, used for treatment of bacterial infection in mammals | TLR1, ABCB11, SLC7A1 | CFTR 30/4885GOPC 4484/4885SLC6A2 2005/4885 |
| US-20170349587-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | PREP, UNG, DPP4 | CFTR 4487/4885GOPC 4199/4885SLC6A2 4424/4885 |
| US-20230295181-A1 | INHIBITOR OF APOPTOSIS (IAP) PROTEIN ANTAGONISTS | API5, XIAP, BIRC5 | CFTR 3862/4885GOPC 3152/4885SLC6A2 4825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.